The clinical significance of CA-125 in pulmonary tuberculosis

Kim, Eun Sun; Park, Kyoung Un; Song, Junghan; Lim, Hyungjun; Cho, Young Jae; Yoon, Ho Il; Lee, Jae-Ho; Lee, Choon Taek; Park, Jong Sun

doi:10.1016/j.tube.2012.10.014

Cited by 22 publications

(20 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These high levels fall after adequate treatment and are considered as a useful marker in the diagnosis and follow-up of patients with TB peritonitis. 15 Although our case is not the first case report on such a severe complication as similar cases were previously reported in the literature, 6,7,16 it adds to previous reports and reinforces the recommendation that all patients should be made full aware of the potential systemic and delayed complications of BCG immunotherapy.…”

Section: Discussionsupporting

confidence: 85%

DisseminatedMycobacterium BovisInfection Complicating Intravesical BCG Instillation for the Treatment of Superficial Transitional Cell Carcinoma of the Bladder

Elzein

Albogami

Saad

et al. 2016

Clin Med Insights Case Rep

View full text Add to dashboard Cite

BACKGROUNDIntravesical instillation of Bacillus Calmette–Guérin (BCG) remains a first-line treatment for superficial transitional cell carcinoma of the bladder. Although its use is relatively safe, severe complications such as granulomatous hepatitis, osteomyelitis, pneumonitis, and sepsis occur in few patients. Complications of intravesical instillation of BCG can be local or systemic, with early or late presentation.CASE PRESENTATIONHere, we report an 88-year-old man who developed fever, rigors, and episodes of syncope following fourth intravesical BCG instillation for the treatment of superficial transitional cell carcinoma of the bladder. Pancytopenia, disseminated intravascular coagulation, ground glass appearance on computerized tomography of the chest scan in addition to multiple bone marrow granulomas, suggested the diagnosis of disseminated BCG infection. All these features recovered on antituberculosis treatment.CONCLUSIONOur case study highlights the importance of early recognition and prompt treatment of patients with disseminated BCG infection following intravesical instillation. Although isolation of mycobacterium is desirable to make the diagnosis, it is not unusual to have negative smears and cultures and this should not be used to dismiss the possibility of BCG infection.

show abstract

Section: Discussionsupporting

confidence: 85%

DisseminatedMycobacterium BovisInfection Complicating Intravesical BCG Instillation for the Treatment of Superficial Transitional Cell Carcinoma of the Bladder

Elzein

Albogami

Saad

et al. 2016

Clin Med Insights Case Rep

View full text Add to dashboard Cite

show abstract

“…(1) Some critical proteins of the Wnt pathway might be predictive factors of the outcome of TB treatment. (2) Some proteins of the Wnt pathway might be biomarkers to distinguish severe and mild TB (there is still the lack of a sensitive biomarker to define TB lesion severity except image features and some uncertain markers [27–28]). (3) The Wnt pathway or unknown molecule(s) associated with the Wnt pathway might be a potential immunotherapeutic target for TB patients.…”

Section: Discussionmentioning

confidence: 99%

Impairment of Wnt/β-catenin signaling in blood cells of patients with severe cavitary pulmonary tuberculosis

et al. 2017

View full text Add to dashboard Cite

Tuberculosis (TB) remains as a leading infectious disease worldwide. Our previous study showed interferon (IFN)-γ and CD3 T cell impairment in patients with severe cavitary pulmonary TB (PTB). However, the cause of the change in immune responses during the progression of TB is still poorly understood. In this study, eight newly diagnosed patients with severe cavitary and mild lesion non-cavity PTB were recruited, and three healthy volunteers were recruited as the control. RNA extracted from blood was tested by whole genome oligo microarrays. A PCR array was used to further test the same samples. Two additional groups of patients were recruited according to the same criteria with healthy control(HC) recruited as well and subjected to peripheral blood mononuclear cell isolation (PBMC)and analysis of TCF-7, β-catenin, cyclin D2, IFN-γ, and tumor necrosis factor (TNF)-α expression in CD14- cells (lymphocytes) and CD14+ cells by quantitative PCR. The changes of expression of β-catenin, CD69+ and IFN-γ by CD3+, CD14- and CD14+ cells in vitro with stimulation of LiCl were tested by flow cytometry. Whole genome oligo microarrays showed a significant decrease in expression of the Wnt signaling pathway in severe PTB patients. Further analysis of the Wnt pathway by PCR array indicated that TCF-7, β-catenin, and cyclin D2 expression was significantly reduced in severe PTB patients compared with mild PTB patients. In the additionally recruited patients, TCF-7, β-catenin, and cyclin D2 were expressed in both CD14+ and CD14- cells, while β-catenin was decreased significantly in CD14- cells compared with CD14+ cells in severe PTB patients, and IFN-γ and TNF-α expression in CD14- cells was also reduced significantly in severe PTB patients. β-catenin can directly trigger T cell activation and IFN-γsecretion in PBMCs stimulated for 24 hours. These findings indicate that Wnt pathway and its key genes, such as β-catenin, were impaired in blood cells of patients with severe PTB. Therefore, Wnt/β-catenin pathway is closely associated with T cell proliferation and TB lesion deterioration.

show abstract

“…In addition to its normal functional role, deregulated expression of MUC16 has been implicated in several diseases, which include dry eye disease (11), psoriasis (16), Sjogren's syndrome (17), ulcerative colitis (18), pulmonary tuberculosis (19), and cancer (20–22). This indicates that MUC16 has a context‐dependent function and further studies are required to elucidate these functions.…”

mentioning

confidence: 99%

MUC16: molecular analysis and its functional implications in benign and malignant conditions

et al. 2014

View full text Add to dashboard Cite

MUC16 is a high-molecular-weight glycoprotein that is expressed by the various epithelial cell surfaces of the human body to protect the cell layer from a myriad of insults. It is the largest mucin known to date, with an ∼22,152 aa sequence. Structurally, MUC16 is characterized into 3 distinct domains: the amino terminal, the tandem repeat, and the carboxyl terminal domain, with each domain having unique attributes. The extracellular portion of MUC16 is shed into the bloodstream and serves as a biomarker for diagnosing and monitoring patients with cancer; however, its functional role in cancer is yet to be elucidated. Several factors contribute to this challenge, which include the large protein size; the extensive glycosylation that the protein undergoes, which confers functional heterogeneity; lack of specific antibodies that detect the unique domains of MUC16; and the existence of splicing variants. Despite these limitations, MUC16 has been established as a molecule of significant application in cancer. Hence, in this review, we discuss the various aspects of MUC16, which include its discovery, structure, and biological significance both in benign and malignant conditions with an attempt to dissect its functional relevance

show abstract

The clinical significance of CA-125 in pulmonary tuberculosis

Cited by 22 publications

References 14 publications

DisseminatedMycobacterium BovisInfection Complicating Intravesical BCG Instillation for the Treatment of Superficial Transitional Cell Carcinoma of the Bladder

DisseminatedMycobacterium BovisInfection Complicating Intravesical BCG Instillation for the Treatment of Superficial Transitional Cell Carcinoma of the Bladder

Impairment of Wnt/β-catenin signaling in blood cells of patients with severe cavitary pulmonary tuberculosis

MUC16: molecular analysis and its functional implications in benign and malignant conditions

Contact Info

Product

Resources

About